BRE 360
Description:
Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC)
Study Status: Approved
Phase Of Study:
BRE 360
Available in 3 location(s)
Description:
Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC)
Locations:
Tennessee Oncology - Chattanooga
2200 E. Third Street Suite 100
Chattanooga, TN 37404
USA
Get Directions
844-482-4812
Tennessee Oncology - Chattanooga
605 Glenwood Drive Suite 200
Chattanooga, TN 37404
USA
Get Directions
844-482-4812
Tennessee Oncology - Chattanooga
2390 North Ocoee Street
Cleveland, TN 37311
USA
Get Directions
844-482-4812